title: Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis.
abstract: Thalidomide is an immunomodulating agent which reverses many of the cytokine disturbances seen in systemic onset juvenile idiopathic arthritis (SoJIA) with inadequate response to other treatments. We report 3 cases of recalcitrant SoJIA which improved dramatically after treatment with thalidomide.
  
  
  METHODS
  Three children aged 9, 8, and 6 years diagnosed with SoJIA treated with conventional therapy including NSAIDs, corticosteroids, methotrexate and etanercept failed to respond fully and their condition worsened. Thalidomide was begun based on two previous reports showing its efficacy in recalcitrant SoJIA.
  
  
  RESULTS
  Thalidomide produced successful remission of the disease in all 3 patients according to the preliminary criteria for inactive disease and clinical remission of JIA.
  
  
  CONCLUSIONS
  Thalidomide may be a viable, alternative corticoid-sparing therapy in patients with recalcitrant, multidrug-resistant SoJIA.
authors: Systemic Autoimmune Diseases Research Unit, HGZ #36, CMN Manuel Avila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico. 30591mgc@comb.es
authors: Mario
authors: M
authors: García-Carrasco
authors: Salvador
authors: S
authors: Fuentes-Alexandro
authors: Ricardo O
authors: RO
authors: Escárcega
authors: Jorge
authors: J
authors: Rojas-Rodriguez
authors: Luis E
authors: LE
authors: Escobar
mesh_terms: D017668:Age of Onset; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide